TABLE 1.

Thrombotic microangiopathy incidence in included cohort and single-arm studies.

Study	Study design	Study population	Total TMA incidence	Systemic TMA incidence	Renal-limited TMA incidence	Study follow-up time (month)	C4d+	C4d−	Tacrolimus base regimen	Cyclosporine base regimen	Acute antibody-mediated rejection	Acute cell-mediated rejection	ABO incompatible
Baid, 1999 [33]	Single-arm	KAR	3.2% (12/379)		3.2% (12/379)	84
Braet, 2016 [34]	Single-arm	KAR	2.20%		N/A	428
Caires, 2012 [35]	Single-arm	KAR	1.1% (17/1,549)		1.1% (17/1,549)	132
Dessaix, 2019 [36]	Single-arm	KAB	4.80%			6.6
Doradla, 2020 [37]	Single-arm	KAR	0.85% (17/2,000)	0.2% (4/2,000)	0.65% (13/2,000)
Fortin, 2004 [38]	Cohort	KAR	3.53% (13/368)		3.53% (13/368)				1.29% (3/233)	3.70% (2/54)
Franco, 2003 [39]	Single-arm	KAR	0.26% (10/3,862)	0.26% (10/3,862)		24
Futamura, 2020 [40]	Single-arm	KAR	5.16% (69/1,336)			211
Gumber, 2014 [41]	Single-arm	KAR	2.89% (34/1,175)			72
Kocak, 2015 [42]	Single-arm	KAR	2.72% (13/477)	2.72% (13/477)		36			2.72% (13/477)
Langer, 2001 [43]	Single-arm	KAR	1.5% (10/672)	1.5% (10/672)		212				1.5% (10/672)
Nava, 2014 [44]	Cohort	KAR	7.3% (36/496)			180				N/A
Oyen, 2006 [45]	Single-arm	KAR	0.82% (7/850)			48				0.82% (7/850)
Ozedemir, 2018 [46]	Single-arm	KAR									33.33% (30/90)	17.6% (9/51)
Reynolds, 2003 [3]	Cohort	KAR	4.9/1,000 PY
Santos, 2003 [47]	Single-arm	KAR	5% (6/115)	5% (6/115)
Satoskar, 2010 [16]	Single-arm	KAB					13.6% (33/243)	23.6% (6/715)
Schwimmer, 2003 [4]	Single-arm	KAR	3% (21/742)	1.07% (8/742)	1.75% (13/742)				52% (11/21)	48% (10/21)
Tasaki, 2019 [17]	Cohort	KAR	7.5% (15/201)	7.5% (15/201)		214							17.2% (15/87)
Zarifian, 1999 [48]	Single-arm	KAR	13.8% (26/188)	1.06% (2/188)	12.7% (24/188)

KAR, kidney allograft recipients; KAB, kidney allograft biopsies; PY, person-years; TMA, thrombotic microangiopathy.